Announced Fri, 3 Jul · 17:34 IST
US FDA inspection at Pithampur facility - 2 procedural observations
Regulatory & Legal View source PDF
RUBICON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+5.5%1-day move
₹1312.10
prior close
₹1330.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.1+2.1+3.2+3.8+5.5+6.8+7.3+9.0+9.7+10.6+20.0———
Up moveDown movePending
AI summary
US FDA conducted an unannounced inspection of Rubicon Research's Pithampur (Madhya Pradesh) manufacturing facility from June 29 to July 3, 2026. This was the first FDA inspection since the facility was acquired last year. A Form 483 was issued with 2 procedural observations, none related to data integrity. The company plans to respond timely and expects commercial operations to ramp up from Q1 CY2027.
Likely market impact
Minor procedural observations, no data integrity issues. Positive outcome expected; supports commercial ramp-up from Q1 CY2027.